Keometformin Tablets 15/850 mg
Metformin Hydrochloride · Pioglitazone Hydrochloride
Prescription medication · Combination
KMS Pharmaceutical Co., Ltd.
MFDS item code 201802861 · Approved 2018.07.10
This product's status changed to Expired on 2023.07.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help control blood sugar levels in patients with Type 2 diabetes. It is particularly prescribed when adequate blood sugar control is difficult with monotherapy using either metformin or pioglitazone. It is also used as a substitute for combination therapy with metformin and pioglitazone. Management of Type 2 diabetes should occur in conjunction with nutritional counseling, weight loss, and physical activity; such lifestyle improvements are crucial for enhancing and maintaining the effects of the medication. Therefore, this medication is used to improve blood sugar control in conjunction with diet and exercise.
For the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this drug once daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start at their existing doses of pioglitazone and metformin. No studies have been conducted to assess the safety and efficacy of switching from another oral antihyperglycemic agent to this drug. Any change in a type 2 diabetes treatment regimen may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this drug. Patients should be carefully monitored for adverse reactions associated with fluid retention after starting this drug or increasing the dose. This drug should generally be administered in divided doses with meals; doing so may reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.
This medication helps control blood sugar levels. However, caution should be exercised for the rare side effect known as lactic acidosis while taking this medication. Lactic acidosis is a serious condition that occurs when there is an excessive accumulation of lactic acid in the body, and symptoms may include difficulty breathing, muscle pain, abdominal pain, and fatigue. If these symptoms occur, consult a physician immediately. Additionally, this medication should not be administered to patients with impaired kidney function or severe heart failure. Given that diminished kidney function can lead to drug accumulation in the body, this increases the risk of side effects. Regular kidney function testing is therefore essential. Patients with impaired liver function should also avoid using this medication, as compromised liver processing of drugs can aggravate side effects. Excessive alcohol intake may affect lactate metabolism when combined with this medication, making it risky; thus, avoidance of alcohol consumption is recommended. This medication may impose a burden on the heart, and patients with heart failure symptoms should be closely monitored. If symptoms of heart failure such as weight gain, swelling, or shortness of breath arise, medical personnel should be informed immediately. Patients with a history of bladder cancer or those with active bladder cancer should not use this medication and should report any new or worsening bladder-related symptoms to their doctor. Women who are pregnant, could become pregnant, or are breastfeeding should not take this medication. While using this medication, symptoms of hypoglycemia, in which blood sugar levels drop too low, may also occur, so caution is warranted when skipping meals or engaging in vigorous exercise. This is especially critical when taking other glucose-lowering agents concurrently. Elderly patients may be at risk for decreased kidney function, so careful dosage adjustments and regular monitoring of kidney function are advised during administration of this medication. If surgery or radiographic examinations using contrast agents are planned, the use of this medication should be temporarily halted, and it should only be resumed after confirming normal kidney function. While taking this medication, it is important to have regular blood sugar, hematological, and liver function tests to ensure there are no abnormalities.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to protect it from air and moisture. The storage temperature should be maintained between 1 and 30 degrees Celsius, and it is advisable to avoid excessively hot or cold places.
White to pale gray rectangular film-coated tablets
30 tablets (10 tablets/PTP*3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Metformin Hydrochloride · Pioglitazone Hydrochloride
Prescription medication · Combination
KMS Pharmaceutical Co., Ltd.
Pioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationMetformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Dalim Biotech Co., Ltd.
CombinationPioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
Metformin Hydrochloride · Pioglitazone Hydrochloride
Prescription medication · Combination
Nexpam Korea Co., Ltd.
CombinationPioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Ilhwa Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.